Journal of Endocrinology and Reproduction

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Thiazolidinedione Class of Anti-Diabetic Drugs Modulate Nuclear Receptor CAR Function


Affiliations
1 Special Centre for Molecular Medicine, Jawaharlal Nehru University New Delhi – 110067, India
     

   Subscribe/Renew Journal


The human body has developed a defence system to prevent the accumulation of endogenous (bile acids, steroids, cholesterol metabolites, neurotransmitters, etc.) as well as exogenous (xenobiotics, clinical drugs, etc.) small molecules at toxic levels. This task is accomplished by ‘drug metabolism and disposition (DMD) machinery’ which entails phase I and phase II enzymes, and phase III transporter proteins. The components of this machinery act in a coordinated manner to biotransform and facilitate the elimination of small toxic molecules from the cellular milieu. Constitutive androstane receptor (CAR), a member of the nuclear receptor superfamily, acts as one of the major transcriptional regulators of the DMD machinery. Prescription of combination therapy is a common regimen during the treatment of diverse metabolic disorders and infectious diseases. In such combination therapies one drug may modulate the expression of genes of DMD, influencing the metabolism of another co-administered drug. This leads to decreased bioavailability or increased toxicity of the latter. Evaluation of drug-drug interactions (DDIs) has now become a major safety concern during drug discovery and development processes. Pre-assessment of the small molecules for modulatory effects on CAR and induction of the components of DMD can resolve the safety concerns, treatment failures and drug withdrawals due to the harmful DDIs. In the present study, we have followed a ‘reverse approach’ to assess CAR activation by drugs previously withdrawn from clinical practices. We selected three redundant members of thiazolidinedione family of anti-diabetic drugs and examined their potential in regulation of CAR and its target gene CYP2B6. These drugs showed differential transcriptional activation of CAR. Two of the TZD i.e., rosiglitazone and pioglitazone enhanced CAR activity by behaving as receptor ligands while the other (troglitazone) did not influence the receptor function and was justly withdrawn since it inflicted cytotoxicity.

Keywords

Anti-Diabetic Drugs, Constitutive Androstane Receptor, Drug Metabolism and Disposition Machinery, Nuclear Receptor, Nuclear Translocation.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Baes M, Gulick T, Choi H–S, Martinoli MG, Simha D, Moore DD. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol Cell Biol. 1994; 14(3):1544–52. PMid:8114692 PMCid:PMC358513

  • Chang TKH. Activation of pregnane x receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J. 2009; 11(3):590–601. PMid:19688601. Available from: https://doi.org/10.1208/s12248–0099135–y.

  • Chaturvedi NK, Kumar S, Negi S, Tyagi RK. Endocrine disruptors provoke differential modulatory responses on androgen receptor and pregnane and xenobiotic receptor:potential implications in metabolic disorders. Mol Cell Biochem. 2010; 345(1–2):291–308. PMid:20830510. Available from: https://doi.org/10.1007/s11010–010–0583–6.

  • Dash AK, Yende AS, Kumar S, Singh, SK, Kotiya D, Rana M et al. The Constitutive Androstane Receptor (CAR): a nuclear receptor in health and disease. J Endocrinol Reprod. 2014; 18(2):59–74.

  • Dash AK, Tyagi RK. A compendium of nuclear receptors: The superfamily of ligand–modulated transcription factors. J Endocrinol Reprod. 2016; 20(1):1–27.

  • Dash AK, Yende AS, Tyagi RK. Novel application of red fluorescent protein (DsRed–Express) for the study of functional dynamics of nuclear receptors. J Fluoresc. 2017; 27(4):1225–1231. PMid:28470379. Available from: https://doi.org/10.1007/s10895–017–2109–z.

  • Dong B, Saha PK, Huang W, Chen W, Abu–Elheiga LA, Wakil SJ et al. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc Natl Acad Sci USA. 2009; 106(44):18831–6. PMid:19850873. Available from: https://doi.org/10.1073/pnas.0909731106.

  • Ducharme MP, Bernstein ML, Granvil CP, Gehrcke B, Wainer IW. Phenytoin–induced alteration in the N–dechloroethylation of ifosfamide stereoisomers. Cancer Chemother Pharmacol. 1997; 40(6):531–533. PMid:9332469. Available from: https://doi.org/10.1007/s002800050698.

  • Gao J, Xie W. Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol Sci. 2012; 33(10):552–8. PMid:22889594. Available from: https://doi.org/10.1016/j.tips.2012.07.003.

  • Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the Nuclear Receptor superfamily. Nat Rev Drug Discov. 2004; 3(11):950–64. PMid:15520817. Available from: https://doi.org/10.1038/nrd1551.

  • Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther. 2007; 81(2):298–304. PMid: 17259955. Available from: https://doi.org/10.1038/sj.clpt.6100054.

  • Huang W, Zhang J, Wei P, Schrader WP, Moore DD. Meclizine is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for human CAR. Mol Endocrinol. 2004; 18(10):2402–2408. PMid:15272053. Available from: https://doi.org/10.1210/me.2004–0046.

  • Kaiser D, Oetjen E. Something old, something new and something very old: drugs for treating type 2 diabetes. Br J Pharmacol. 2014; 171(12):2940–50. PMid:24641580. Available from: https://doi.org/10.1111/bph.12624.

  • Kumar S, Saradhi M, Chaturvedi NK, Tyagi RK. Intracellular localization and nucleocytoplasmic trafficking of steroid receptors: An overview. Mol Cell Endocrinol. 2006; 246(12):147–56. PMid:16388893. Available from: https://doi.org/10.1016/j.mce.2005.11.028.

  • Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015; 58(3):493–504. PMid:25481707. Available from: https://doi.org/10.1007/s00125–014–3456–9.

  • Lim PLK, Liu J, Go ML, Boelsterli UA. The mitochondrial superoxide/thioredoxin–2/ask1 signaling pathway is critically involved in troglitazone–induced cell injury to human hepatocytes. Toxicol Sci. 2008; 101(2):341–349. PMid:17975114. Available from: https://doi.org/10.1093/toxsci/kfm273.

  • Mackowiak B, Wang H. Mechanisms of xenobiotic receptor activation: Direct vs. indirect. Biochim Biophys Acta. 2016; 1859(9):1130–1140. PMid:26877237. Available from: https://doi.org/10.1016/j.bbagrm.2016.02.006.

  • Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/ pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genom. 2007; 17(6):431–45. PMid:17502835. Available from: https://doi.org/10.1097/FPC.0b013e328045c4fb.

  • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356(24):2457–2471. PMid: 17517853. Available from: https://doi.org/10.1056/ NEJMoa072761.

  • Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta–analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010; 170(14):1191–1201. PMid:20656674. Available from: https://doi.org/ 10.1001/archinternmed.2010.207.

  • Prakash C, Zuniga B, Song CS, Jiang S, Cropper J, Park S et al. Nuclear receptors in drug metabolism, drug response and drug interactions. Nucl Receptor Res. 2015; 2:101178. PMCid:PMC4963026.

  • Rana M, Devi S, Gourinath S, Goswami R, Tyagi RK. A comprehensive analysis and functional characterization of naturally occurring non–synonymous variants of nuclear receptor PXR. Biochim Biophys Acta. 2016; 1859(9):1183–97. PMid:26962022. Available from: https://doi.org/10.1016/j.bbagrm.2016.03.001.

  • Staudinger JL, Lichti K. Cell signaling and nuclear receptors: New opportunities for molecular pharmaceuticals in liver disease. Mol Pharm. 2008; 5(1):17–34. PMid:18159925. Available from: https://doi.org/10.1021/mp700098c.

  • Taylor C, Hobbs FR. Type 2 diabetes, thiazolidinediones and cardiovascular risk. Br J Gen Pract. 2009; 59(564):520–524. PMid:19567003. Available from: https://doi.org/10.3399/bjgp09X453440


Abstract Views: 315

PDF Views: 1




  • Thiazolidinedione Class of Anti-Diabetic Drugs Modulate Nuclear Receptor CAR Function

Abstract Views: 315  |  PDF Views: 1

Authors

Shashi Kala Singh
Special Centre for Molecular Medicine, Jawaharlal Nehru University New Delhi – 110067, India
Rakesh K. Tyagi
Special Centre for Molecular Medicine, Jawaharlal Nehru University New Delhi – 110067, India

Abstract


The human body has developed a defence system to prevent the accumulation of endogenous (bile acids, steroids, cholesterol metabolites, neurotransmitters, etc.) as well as exogenous (xenobiotics, clinical drugs, etc.) small molecules at toxic levels. This task is accomplished by ‘drug metabolism and disposition (DMD) machinery’ which entails phase I and phase II enzymes, and phase III transporter proteins. The components of this machinery act in a coordinated manner to biotransform and facilitate the elimination of small toxic molecules from the cellular milieu. Constitutive androstane receptor (CAR), a member of the nuclear receptor superfamily, acts as one of the major transcriptional regulators of the DMD machinery. Prescription of combination therapy is a common regimen during the treatment of diverse metabolic disorders and infectious diseases. In such combination therapies one drug may modulate the expression of genes of DMD, influencing the metabolism of another co-administered drug. This leads to decreased bioavailability or increased toxicity of the latter. Evaluation of drug-drug interactions (DDIs) has now become a major safety concern during drug discovery and development processes. Pre-assessment of the small molecules for modulatory effects on CAR and induction of the components of DMD can resolve the safety concerns, treatment failures and drug withdrawals due to the harmful DDIs. In the present study, we have followed a ‘reverse approach’ to assess CAR activation by drugs previously withdrawn from clinical practices. We selected three redundant members of thiazolidinedione family of anti-diabetic drugs and examined their potential in regulation of CAR and its target gene CYP2B6. These drugs showed differential transcriptional activation of CAR. Two of the TZD i.e., rosiglitazone and pioglitazone enhanced CAR activity by behaving as receptor ligands while the other (troglitazone) did not influence the receptor function and was justly withdrawn since it inflicted cytotoxicity.

Keywords


Anti-Diabetic Drugs, Constitutive Androstane Receptor, Drug Metabolism and Disposition Machinery, Nuclear Receptor, Nuclear Translocation.

References





DOI: https://doi.org/10.18311/jer%2F2017%2F20188